Jiang­su Hen­grui, a 55-year-old drug­mak­er that has be­come one of Chi­na’s lead­ing forces in biotech, ex­pects net pro­ceeds of about 9.4 bil­lion Hong Kong dol­lars … ...

AbbVie partners with ADARx Pharmaceuticals in $335M upfront deal for siRNA tech collaboration across neuroscience, immunology ...

HHS Secretary Robert F. Kennedy Jr. faced hours of congressional grilling on Wednesday over his proposed budget cuts and ...

Three cell & gene therapy groups - ISCT, ARM & ASGCT - jointly call for 10-year global ban on human germline gene editing, ...

Sanofi announced plans to invest “at least” $20 billion in the US through 2030, following similar commitments made by several ...

Novo Nordisk is partnering with Septerna in a $2B+ deal to develop oral small molecules for obesity and diabetes, focusing on ...

The Trump administration laid out for the first time how Part B drugs could be selected for Medicare drug price negotiations ...

Plus, news about Allogene, Kyverna, Sernova, ADC Therapeutics, Acelyrin, Alumis, Atara, Lava Therapeutics and Repare Therapeutics ...

Omada, the virtual chronic care provider, joins virtual physical therapy company Hinge Health in testing the public market’s ...

Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with ...

Bayer cuts 2,000 jobs in Q1 2025, reaching 11,000 total layoffs amid reorganization. CEO Bill Anderson reports strong pharma ...

A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential ...